Italy - English - Ministero della Salute

international medical service - coldsterilizing solution, based on adazone and peracetic acid, to be used in ers, endoscopes sterilizer. - activated and diluted solution adazone (5,7-diphenyl-1,3 diazoadamantan-6-one) 0.00055 g., peracetic acid 0,0900 g., excipients and purified water q.s. to 100 ml. - adazone and peracetic acid - connect one bottle of solution a and one bottle of solution b to the automated single shot sterilizer endoscope reprocessors ers (manufactured by cisa) according to the operator's manual.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 1 mg - diluent, not applicable - excipient ingredients: water for injections - injection: intravenous use, for status epilepticus.

United States - English - NLM (National Library of Medicine)

mylan institutional llc - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil (mmf) for injection is indicated for the prophylaxis of organ rejection, in adult recipients of allogeneic kidney [see clinical studies (14.1)], heart [see clinical studies (14.2)] or liver transplants [see clinical studies (14.3)] , in combination with other immunosuppressants. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil for injection is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (mmf), mycophenolic acid (mpa) or any component of the drug product. mycophenolate mofetil for injection is contraindicated in patients who are allergic to polysorbate 80 (tween). pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. to report a pregnancy or obtain information about the registry, visit www.mycophenolaterems.com or call

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - ethacrynate sodium (unii: k41myv7mpm) (ethacrynic acid - unii:m5dp350vzv) - ethacrynate sodium is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. - 1.treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. - 2.short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. - 3.short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. - 4.intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. all diuretics, including ethacrynic acid, are contraindicated in anuria. if increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. in a few patients this diuretic has produced severe, watery d

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftaroline fosamil 600mg equivalent to ceftaroline fosamil acetic acid solvate monohydrate 668.4 mg - powder for injection - 600 mg - active: ceftaroline fosamil 600mg equivalent to ceftaroline fosamil acetic acid solvate monohydrate 668.4 mg excipient: arginine - zinforo is indicated for the treatment of patients with the following infections proven or strongly suspected to be caused by the designated susceptible bacteria: - complicated skin and soft tissue infections (cssti) - community-acquired pneumonia (cap) consideration should be given to official guidance on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - ethacrynic acid (unii: m5dp350vzv) (ethacrynic acid - unii:m5dp350vzv) - ethacrynic acid 25 mg - edecrin is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. all diuretics, including ethacrynic acid, are contraindicated in anuria. if increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. in a few patients this diuretic has produced severe, watery diarrhea. if this occurs, it should be discontinued and not used again. until further experience in infants is accumulated, therapy with oral and parenteral edecrin is contraindicated. hypersensitivity to any component of this product.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - ethacrynate sodium (unii: k41myv7mpm) (ethacrynic acid - unii:m5dp350vzv) - ethacrynic acid 50 mg in 50 ml - ethacrynic acid is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. - treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. - short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. - short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. - intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. all diuretics, including ethacrynic acid, are contraindicated in anuria. if increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. in a few patients this diuretic has produced severe, watery diarrhea. if

United States - English - NLM (National Library of Medicine)

bausch health us, llc - ethacrynic acid (unii: m5dp350vzv) (ethacrynic acid - unii:m5dp350vzv) - ethacrynic acid 25 mg - edecrin is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. all diuretics, including ethacrynic acid, are contraindicated in anuria. if increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. in a few patients this diuretic has produced severe, watery diarrhea. if this occurs, it should be discontinued and not used again. until further experience in infants is accumulated, therapy with oral and parenteral edecrin is contraindicated. hypersensitivity to any component of this product.

Canada - English - Health Canada

teva canada limited - zoledronic acid (zoledronic acid monohydrate) - solution - 4mg - zoledronic acid (zoledronic acid monohydrate) 4mg - bone resorption inhibitors

Canada - English - Health Canada

dr reddy's laboratories ltd - zoledronic acid (zoledronic acid monohydrate) - solution - 4mg - zoledronic acid (zoledronic acid monohydrate) 4mg - bone resorption inhibitors